Brief: Pennant Group Q2 Adjusted EPS USD 0.27 Vs. IBES Estimate USD 0.27

Pennant group

06/08/2025 21:05

Overview

Pennant Q2 2025 revenue grows 30.1% yr/yr, beating analyst expectations

Adjusted EPS for Q2 meets analyst expectations at $0.27

Adjusted EBITDA for Q2 rises to $28.2 mln, beating estimates

Outlook

Co, provides home health, hospice, and senior living services, expects 2025 revenue between $852.8 mln and $887.6 mln

Pennant projects 2025 adjusted EPS of $1.09 to $1.15

Company anticipates 2025 adjusted EBITDA between $69.1 mln and $72.7 mln

Guidance includes expenses for UnitedHealth, Amedisys transaction

Result Drivers

HOME HEALTH GROWTH - Home health segment revenue rose 32.5% yr/yr, driven by increased admissions

HOSPICE EXPANSION - Hospice average daily census increased 21.4% yr/yr, contributing to revenue growth

SENIOR LIVING REVENUE - Senior living segment revenue grew 23.1% yr/yr, aided by higher revenue per occupied room

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$219.50 mln
$210.60 mln (5 Analysts)
Q2 Adjusted EPS
Meet
$0.27
$0.27 (5 Analysts)
Q2 EPS
$0.2
Q2 Net Income
$7.10 mln
Q2 Adjusted EBITDA
Beat
$28.20 mln
$16.40 mln (5 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy"

Wall Street's median 12-month price target for Pennant Group Inc is $33.00, about 32.8% above its August 5 closing price of $22.19

The stock recently traded at 19 times the next 12-month earnings vs. a P/E of 22 three months ago

Press Release: ID:nGNXbPXyWw

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)